% | $
Quotes you view appear here for quick access.

Progenics Pharmaceuticals, Inc. Message Board

  • jimturner54321 jimturner54321 Jan 30, 2014 9:30 PM Flag

    Conclusions released

    In taxane-experienced mCRPC treated with PSMA ADC at doses of 2.3 mg/kg, reductions of PSA ≥30% are seen in ~38% and reductions of ≥50% are seen in ~16% of patients • CTC conversion from unfavorable to fa vorable occurs in ~45% of patients • PSMA Expression correlates well to PSA and CTC (p=0.019) response to PSMA ADC • Low NE markers correlate well to PSA (p=0.012) response with CTC reduction of 50% in 78% of patients • 2.3 mg/kg is generally well tolerated and appears to be better tolerated than 2.5 mg/kg • A taxane-naïve cohort is ongoing

    SortNewest  |  Oldest  |  Most Replied Expand all replies
4.89+0.12(+2.52%)May 27 4:00 PMEDT